WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
New research labs and process development services to enable next generation therapeutics
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Modernization and supply chain diversity drive new growth
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Subscribe To Our Newsletter & Stay Updated
